{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:23:50Z","timestamp":1790879030974,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To stop the spread of the COVID-19 disease, it is crucial to create molecular tools to investigate and diagnose COVID-19. Current efforts focus on developing specific neutralizing monoclonal antibodies (NmAbs) elicited against the receptor-binding domain (RBD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the present study, recombinant RBD (rRBD) protein was produced in E. coli, followed by immunizing mice with purified rRBD. ELISA was applied to screen the hybridomas for positive reactivity with rRBD protein. The linear and conformational epitopes of the mAbs were subsequently identified using western blot. Finally, the reactivity, affinity, and neutralization activity of the purified mAbs were evaluated using ELISA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All mAbs exhibited similar reactivity trends towards both eukaryotic RBD and prokaryotic rRBD in ELISA. Among them, 2E7-D2 and 2B4-G8 mAbs demonstrated higher reactivity than other mAbs. Additionally, in western blot assays, these two mAbs could detect reducing and non-reducing rRBD, indicating recognition of linear epitopes. Notably, five mAbs effectively blocked rRBD- angiotensin-converting enzyme 2 (ACE2) interaction, while two high-affinity mAbs exhibited potent neutralizing activity against eukaryotic RBD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the current study, we generated and characterized new RBD-specific mAbs using the hybridoma technique that recognized linear and conformational epitopes in RBD with neutralization potency. Our mAbs are novel candidates for diagnosing and treating SARS-CoV-2.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-024-02304-2","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T03:02:14Z","timestamp":1707188534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes"],"prefix":"10.1186","volume":"21","author":[{"given":"Seyed Mostafa Mostafavi","family":"Zadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Ahmad","family":"Bayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosein","family":"Shahsavarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feridoun","family":"Karimi-Busheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafar","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Ghods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Madjd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"issue":"5","key":"2304_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/1744666X.2020.1750954","volume":"16","author":"A Saghazadeh","year":"2020","unstructured":"Saghazadeh A, Rezaei N. Immune-epidemiological parameters of the novel coronavirus\u2014a perspective. Expert Rev Clin Immunol. 2020;16(5):465\u201370.","journal-title":"Expert Rev Clin Immunol"},{"issue":"129","key":"2304_CR2","doi-asserted-by":"publisher","first-page":"110337","DOI":"10.1016\/j.biopha.2020.110337","volume":"1","author":"L Jahanshahlu","year":"2020","unstructured":"Jahanshahlu L, Rezaei N. Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother. 2020;1(129):110337.","journal-title":"Biomed Pharmacother"},{"key":"2304_CR3","unstructured":"Covid-19 monoclonal antibodies: monoclonal antibodies to SARS-CoV-2. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of diabetes and digestive and kidney diseases; 2012."},{"key":"2304_CR4","doi-asserted-by":"crossref","unstructured":"Wang K, Chen W, Zhou Y-S, Lian J-Q, Zhang Z, Du P, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020:2020.03.14.988345.","DOI":"10.1101\/2020.03.14.988345"},{"issue":"6","key":"2304_CR5","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.immuni.2022.05.005","volume":"55","author":"H Gruell","year":"2022","unstructured":"Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Antibody-mediated neutralization of SARS-CoV-2. Immunity. 2022;55(6):925\u201344.","journal-title":"Immunity"},{"issue":"1","key":"2304_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/vaccines11010023","volume":"11","author":"D Gupta","year":"2022","unstructured":"Gupta D, Kumar M, Sharma P, Mohan T, Prakash A, Kumari R, Kaur P. Effect of double mutation (L452R and E484Q) on the binding affinity of monoclonal antibodies (MAbs) against the RBD\u2014a target for vaccine development. Vaccines. 2022;11(1):23.","journal-title":"Vaccines"},{"issue":"5","key":"2304_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41587-020-0512-5","volume":"38","author":"B Kelley","year":"2020","unstructured":"Kelley B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol. 2020;38(5):540\u20135.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2304_CR8","doi-asserted-by":"publisher","first-page":"e0135221","DOI":"10.1128\/Spectrum.01352-21","volume":"9","author":"M Yang","year":"2021","unstructured":"Yang M, Li J, Huang Z, Li H, Wang Y, Wang X, et al. Structural basis of a human neutralizing antibody specific to the SARS-CoV-2 spike protein receptor-binding domain. Microbiology spectrum. 2021;9(2):e0135221.","journal-title":"Microbiology spectrum"},{"issue":"2","key":"2304_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.immuni.2017.07.009","volume":"47","author":"S Bournazos","year":"2017","unstructured":"Bournazos S, Ravetch JV. Fc\u03b3 receptor function and the design of vaccination strategies. Immunity. 2017;47(2):224\u201333.","journal-title":"Immunity"},{"issue":"12","key":"2304_CR10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/vaccines9121376","volume":"9","author":"JJ Morales-N\u00fa\u00f1ez","year":"2021","unstructured":"Morales-N\u00fa\u00f1ez JJ, Mu\u00f1oz-Valle JF, Torres-Hern\u00e1ndez PC, Hern\u00e1ndez-Bello J. Overview of neutralizing antibodies and their potential in COVID-19. Vaccines. 2021;9(12):1376.","journal-title":"Vaccines"},{"key":"2304_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev-immunol-032712-100001","volume":"31","author":"S Jost","year":"2013","unstructured":"Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol. 2013;31:163\u201394.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2304_CR12","doi-asserted-by":"publisher","first-page":"e0181421","DOI":"10.1128\/spectrum.01814-21","volume":"10","author":"CJ Li","year":"2022","unstructured":"Li CJ, Chao TL, Chang TY, Hsiao CC, Lu DC, Chiang YW, et al. Neutralizing monoclonal antibodies inhibit SARS-CoV-2 infection through blocking membrane fusion. Microbiol Spectr. 2022;10(2):e0181421.","journal-title":"Microbiol Spectr"},{"issue":"7821","key":"2304_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450\u20136.","journal-title":"Nature"},{"key":"2304_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/978-1-4939-2205-5_15","volume":"1258","author":"A Singh","year":"2015","unstructured":"Singh A, Upadhyay V, Panda AK. Solubilization and refolding of inclusion body proteins. Methods Mol Biol. 2015;1258:283\u201391.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"2304_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/0471140864.ps0304s48","volume":"48","author":"BJ Olson","year":"2007","unstructured":"Olson BJ, Markwell J. Assays for determination of protein concentration. Curr Protoc Protein Sci. 2007;48(1):3\u20134.","journal-title":"Curr Protoc Protein Sci"},{"key":"2304_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-4939-2742-5_2","volume-title":"ELISA: methods and protocols","author":"RM Hnasko","year":"2015","unstructured":"Hnasko RM, Stanker LH. Hybridoma technology. In: Hnasko R, editor. ELISA: methods and protocols. New York: Springer; 2015. p. 15\u201328."},{"issue":"4","key":"2304_CR17","first-page":"212","volume":"5","author":"AA Bayat","year":"2013","unstructured":"Bayat AA, Yeganeh O, Ghods R, Zarnani AH, Ardekani RB, Mahmoudi AR, et al. Production and characterization of a murine monoclonal antibody against human ferritin. Avicenna J Med Biotechnol. 2013;5(4):212\u20139.","journal-title":"Avicenna J Med Biotechnol"},{"key":"2304_CR18","doi-asserted-by":"crossref","unstructured":"Greenfield EA. Polyethylene glycol fusion for hybridoma production. Cold Spring Harbor Protoc 2018; 2018(3).","DOI":"10.1101\/pdb.prot103176"},{"issue":"1\u20132","key":"2304_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0022-1759(87)90187-6","volume":"100","author":"JD Beatty","year":"1987","unstructured":"Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods. 1987;100(1\u20132):173\u20139.","journal-title":"J Immunol Methods"},{"issue":"1","key":"2304_CR20","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s41467-022-29288-3","volume":"13","author":"L Peng","year":"2022","unstructured":"Peng L, Hu Y, Mankowski MC, Ren P, Chen RE, Wei J, et al. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Nat Commun. 2022;13(1):1638.","journal-title":"Nat Commun"},{"key":"2304_CR21","unstructured":"https:\/\/covid19.who.int WHOWCC-DaoAAo."},{"issue":"4","key":"2304_CR22","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jmv.27526","volume":"94","author":"S Kumar","year":"2022","unstructured":"Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol. 2022;94(4):1641\u20139.","journal-title":"J Med Virol"},{"issue":"4","key":"2304_CR23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cell.2022.01.001","volume":"185","author":"P Han","year":"2022","unstructured":"Han P, Li L, Liu S, Wang Q, Zhang D, Xu Z, et al. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell. 2022;185(4):630-40.e10.","journal-title":"Cell"},{"issue":"23","key":"2304_CR24","doi-asserted-by":"publisher","first-page":"9167","DOI":"10.3390\/ijms21239167","volume":"21","author":"NV Antipova","year":"2020","unstructured":"Antipova NV, Larionova TD, Siniavin AE, Nikiforova MA, Gushchin VA, Babichenko II, Volkov AV, Shakhparonov MI, Pavlyukov MS. Establishment of Murine hybridoma cells producing antibodies against spike protein of SARS-CoV-2. Int J Mol Sci. 2020;21(23):9167.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"2304_CR25","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1021\/acs.analchem.1c00893","volume":"93","author":"C Gst\u00f6ttner","year":"2021","unstructured":"Gst\u00f6ttner C, Zhang T, Resemann A, Ruben S, Pengelley S, Suckau D, et al. Structural and functional characterization of SARS-CoV-2 RBD domains produced in mammalian cells. Anal Chem. 2021;93(17):6839\u201347.","journal-title":"Anal Chem"},{"issue":"5","key":"2304_CR26","doi-asserted-by":"publisher","first-page":"e4300","DOI":"10.1002\/pro.4300","volume":"31","author":"LR Struble","year":"2022","unstructured":"Struble LR, Smith AL, Lutz WE, Grubbs G, Sagar S, Bayles KW, et al. Insect cell expression and purification of recombinant SARS-COV-2 spike proteins that demonstrate ACE2 binding. Protein Sci. 2022;31(5):e4300.","journal-title":"Protein Sci"},{"issue":"3","key":"2304_CR27","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/10826068.2021.1941106","volume":"52","author":"X Gao","year":"2022","unstructured":"Gao X, Peng S, Mei S, Liang K, Khan MSI, Vong EG, et al. Expression and functional identification of recombinant SARS-CoV-2 receptor binding domain (RBD) from E. coli system. Preparative Biochem Biotechnol. 2022;52(3):318\u201324.","journal-title":"Preparative Biochem Biotechnol"},{"issue":"9","key":"2304_CR28","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1007\/s11095-016-1979-0","volume":"33","author":"S Bobbala","year":"2016","unstructured":"Bobbala S, Hook S. Is there an optimal formulation and delivery strategy for subunit vaccines? Pharm Res. 2016;33(9):2078\u201397.","journal-title":"Pharm Res"},{"issue":"1","key":"2304_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/vaccines10010096","volume":"10","author":"IA Merkuleva","year":"2022","unstructured":"Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA. Comparative immunogenicity of the recombinant receptor-binding domain of protein S SARS-CoV-2 obtained in prokaryotic and mammalian expression systems. Vaccines. 2022;10(1):96.","journal-title":"Vaccines"},{"key":"2304_CR30","unstructured":"Issue information. Curr Protoc Immunol 2020;131(1):e82"},{"issue":"6506","key":"2304_CR31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014\u20138.","journal-title":"Science"},{"issue":"7","key":"2304_CR32","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205\u201311.","journal-title":"Nat Med"},{"issue":"6520","key":"2304_CR33","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1126\/science.abe2402","volume":"370","author":"A Baum","year":"2020","unstructured":"Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370(6520):1110\u20135.","journal-title":"Science"},{"issue":"3","key":"2304_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","volume":"384","author":"P Chen","year":"2021","unstructured":"Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229\u201337.","journal-title":"N Engl J Med"},{"issue":"4","key":"2304_CR35","doi-asserted-by":"publisher","first-page":"109433","DOI":"10.1016\/j.celrep.2021.109433","volume":"36","author":"F Bertoglio","year":"2021","unstructured":"Bertoglio F, F\u00fchner V, Ruschig M, Heine PA, Abassi L, Kl\u00fcnemann T, et al. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep. 2021;36(4):109433.","journal-title":"Cell Rep"},{"issue":"7815","key":"2304_CR36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290\u20135.","journal-title":"Nature"},{"issue":"6506","key":"2304_CR37","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010\u20134.","journal-title":"Science"},{"issue":"1","key":"2304_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell. 2020;182(1):73-84.e16.","journal-title":"Cell"},{"issue":"5517","key":"2304_CR39","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495\u20137.","journal-title":"Nature"},{"issue":"5602","key":"2304_CR40","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/266550a0","volume":"266","author":"G Galfre","year":"1977","unstructured":"Galfre G, Howe SC, Milstein C, Butcher GW, Howard JC. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature. 1977;266(5602):550\u20132.","journal-title":"Nature"},{"key":"2304_CR41","doi-asserted-by":"crossref","unstructured":"Liu X, Gao F, Gou L, Chen Y, Gu Y, Ao L, et al. Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection. bioRxiv. 2020; 2020.05.03.074914.","DOI":"10.1101\/2020.05.03.074914"},{"issue":"7819","key":"2304_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115\u20139.","journal-title":"Nature"},{"issue":"4","key":"2304_CR43","first-page":"170","volume":"4","author":"F Hajighasemi","year":"2012","unstructured":"Hajighasemi F, Khoshnoodi J, Shokri F. Production and characterization of mouse monoclonal antibodies recognizing human pan-IgG specific conformational or linear epitopes. Avicenna J Med Biotechnol. 2012;4(4):170\u20137.","journal-title":"Avicenna J Med Biotechnol"},{"issue":"2","key":"2304_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/vaccines11020287","volume":"11","author":"Y Watanabe","year":"2023","unstructured":"Watanabe Y, Hosokawa N, Yoshida M, Miura T, Kawano M. Identification of closed linear epitopes in S1-RBD and S2-HR1\/2 of SARS-CoV-2 spike protein able to induce neutralizing Abs. Vaccines. 2023;11(2):287.","journal-title":"Vaccines"},{"issue":"1","key":"2304_CR45","doi-asserted-by":"publisher","first-page":"001","DOI":"10.1093\/femspd\/ftac001","volume":"80","author":"F Maghsood","year":"2022","unstructured":"Maghsood F, Shokri MR, Jeddi-Tehrani M, Torabi Rahvar M, Ghaderi A, Salimi V, et al. Identification of immunodominant epitopes on nucleocapsid and spike proteins of the SARS-CoV-2 in Iranian COVID-19 patients. Pathog Dis. 2022;80(1):001.","journal-title":"Pathog Dis"},{"issue":"8","key":"2304_CR46","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/vaccines9080829","volume":"9","author":"J Hong","year":"2021","unstructured":"Hong J, Wang Q, Wu Q, Chen J, Wang X, Wang Y, Chen Y, Xia N. Rabbit monoclonal antibody specifically recognizing a linear epitope in the RBD of SARS-CoV-2 spike protein. Vaccines. 2021;9(8):829.","journal-title":"Vaccines"},{"issue":"6566","key":"2304_CR47","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.abh2315","volume":"374","author":"KM Hastie","year":"2021","unstructured":"Hastie KM, Li H, Bedinger D, Schendel SL, Dennison SM, Li K, et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science. 2021;374(6566):472\u20138.","journal-title":"Science"},{"issue":"13","key":"2304_CR48","doi-asserted-by":"publisher","first-page":"108915","DOI":"10.1016\/j.celrep.2021.108915","volume":"34","author":"Y Li","year":"2021","unstructured":"Li Y, Ma ML, Lei Q, Wang F, Hong W, Lai DY, et al. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1051 COVID-19 patients. Cell Rep. 2021;34(13):108915.","journal-title":"Cell Rep"},{"issue":"1","key":"2304_CR49","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s42003-021-02835-2","volume":"4","author":"WA Haynes","year":"2021","unstructured":"Haynes WA, Kamath K, Bozekowski J, Baum-Jones E, Campbell M, Casanovas-Massana A, et al. High-resolution epitope mapping and characterization of SARS-CoV-2 antibodies in large cohorts of subjects with COVID-19. Commun Biol. 2021;4(1):1317.","journal-title":"Commun Biol"},{"issue":"6","key":"2304_CR50","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/elsc.202000106","volume":"21","author":"Y He","year":"2021","unstructured":"He Y, Qi J, Xiao L, Shen L, Yu W, Hu T. Purification and characterization of the receptor-binding domain of SARS-CoV-2 spike protein from Escherichia coli. Eng Life Sci. 2021;21(6):453\u201360.","journal-title":"Eng Life Sci"},{"issue":"49","key":"2304_CR51","doi-asserted-by":"publisher","first-page":"19309","DOI":"10.1073\/pnas.0709760104","volume":"104","author":"H Ishikawa","year":"2007","unstructured":"Ishikawa H, Kim S, Kwak K, Wakasugi K, Fayer MD. Disulfide bond influence on protein structural dynamics probed with 2D-IR vibrational echo spectroscopy. Proc Natl Acad Sci. 2007;104(49):19309\u201314.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"2304_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/protein\/gzt063","volume":"27","author":"I Bo\u0161njak","year":"2014","unstructured":"Bo\u0161njak I, Bojovi\u0107 V, \u0160egvi\u0107-Bubi\u0107 T, Bielen A. Occurrence of protein disulfide bonds in different domains of life: a comparison of proteins from the protein data bank. Protein Eng Des Sel. 2014;27(3):65\u201372.","journal-title":"Protein Eng Des Sel"},{"issue":"2","key":"2304_CR53","doi-asserted-by":"publisher","first-page":"e1009165","DOI":"10.1371\/journal.ppat.1009165","volume":"17","author":"M Mor","year":"2021","unstructured":"Mor M, Werbner M, Alter J, Safra M, Chomsky E, Lee JC, et al. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. PLoS Pathog. 2021;17(2):e1009165.","journal-title":"PLoS Pathog"},{"issue":"6","key":"2304_CR54","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","volume":"17","author":"X Chen","year":"2020","unstructured":"Chen X, Li R, Pan Z, Qian C, Yang Y, You R, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020;17(6):647\u20139.","journal-title":"Cell Mol Immunol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02304-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02304-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02304-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T06:03:14Z","timestamp":1707458594000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02304-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2304"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02304-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"17 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}